跳至主要内容
临床试验/NCT04730609
NCT04730609招募中4 期

Dexmedetomidine for Treatment of Shivering During Scheduled Elective Cesarean Delivery: Determining the Optimal Dose

Mayo Clinic1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2021年9月21日最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
招募中
发起方
Mayo Clinic
入组人数
40
试验地点
1
主要终点
Shivering will be graded using a five-point scale as outlined by Crossley and Mahajan

研究概览

简要总结

The purpose of this study is to determine the optimum dose of Dexmedetomidine to stop shivering in 90% of patients who experience shivering during scheduled elective cesarean deliveries.

详细描述

Potential subjects will consist of parturients who present for scheduled elective cesarean deliveries. Patients will be recruited and consented for the study pre-operatively and if they display Grade 3 or 4 shivering at the time of delivery then they will be enrolled in the study. Doses of dexmedetomidine will be selected according to a sequential up-and-down method, using a biased coin design to find the estimated dose at which 90% of patients would have desired effect - cessation of shivering within 5 minutes of medication administration. An anesthesia physician not involved in patient care or assessment will prepare the dexmedetomidine for intravenous use. Anesthesia will be initiated with spinal anesthesia with our institution's typical dosing of 1.6 mL 0.75% bupivacaine with dextrose, 15 mcg fentanyl, and 150 mcg morphine.

Shivering will be graded using a five-point scale as outlined by Crossley and Mahajan. Members of the anesthesia team caring for women in the study will be educated on the grading scales.

  • Grade 0: no shivering;
  • Grade 1: one or more of the following: piloerection, peripheral vasoconstriction, peripheral cyanosis, but without visible muscle activity; Grade 2: visible muscle activity confined to one muscle group;
  • Grade 3: visible muscle activity in more than one muscle group;
  • Grade 4: gross muscle activity involving the whole body

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Women presenting for planned cesarean delivery.
  • American Society of Anesthesiology Physical Classification Status 2 or 3; without major medical co-morbidities.
  • Singleton gestation in the 3rd trimester (28-42 weeks gestation).
  • Spinal anesthesia technique Women presenting for planned cesarean delivery.
  • American Society of Anesthesiology Physical Classification Status 2 or 3; without major medical co-morbidities.
  • Singleton gestation in the 3rd trimester (28-42 weeks gestation).
  • Spinal anesthesia technique.

排除标准

  • Any contraindication to spinal anesthesia technique.
  • Allergy or intolerance to dexmedetomidine or clonidine.
  • Oral temperature < 36° Celsius prior to procedure.
  • Unable to give personal consent.
  • PPROM or concern for infection (e.g., chorioamnionitis).
  • Conversion to General Anesthesia prior to randomization.
  • Sedative medications (e.g., fentanyl, midazolam, ketamine, nitrous oxide) administered prior to randomization.

研究组 & 干预措施

Dexmedetomidine

Experimental

IV administration of Dexmedetomidine, using an Up-Down method utilizing a biased coin design to determine that next patient's dose. Initial dose will be 10mcg.

干预措施: Dexmedetomidine (Drug)

结局指标

主要结局

Shivering will be graded using a five-point scale as outlined by Crossley and Mahajan

时间窗: 5 minutes after administration of the drug

Cessation of shivering

次要结局

  • Doses of dexmedetomidine(During intraoperative course)
  • Maternal Heart Rate(During intraoperative course)

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Hans P. Sviggum, M.D.

Principal Investigator

Mayo Clinic

研究点 (1)

Loading locations...

相似试验